Search

After a relapse of sickle cell disease, Armani Rodriguez and his family found new hope and a special bond with Dr. Maria Cancio at MSK Kids.

… Tuesday, October 29, 2024 Armani Rodriguez was only 2 months old when he spent his very first Christmas in a hospital. Now 22 years old, the Brooklyn native can’t recall the searing pain that landed him there, but his mom will never forget. “He was always crying and needing pain medication,” says Awilda

Memorial Medical Care, PC, a practice of Memorial Sloan Kettering Cancer Center physicians, in collaboration with New York Cancer & Blood Specialists (NYCBS), recently announced the opening of a new comprehensive cancer care practice in the Flatbush section of Brooklyn.

… Wednesday, January 4, 2023 New York Cancer & Blood Specialists (NYCBS), one of the fastest-growing community oncology practices in the nation, today announced the opening of a new comprehensive cancer care practice in the Flatbush section of Brooklyn in collaboration with Memorial Medical Care, PC (MMC

The Memorial Sloan Kettering Cancer Center (MSK) community extends our congratulations to Board of Trustees member David M. Rubenstein, who received the Presidential Medal of Freedom — the nation’s highest civilian honor — earlier this month.

… Wednesday, January 22, 2025 David M. Rubenstein The Memorial Sloan Kettering Cancer Center (MSK) community extends our congratulations to Board of Trustees member David M. Rubenstein, who received the Presidential Medal of Freedom — the nation’s highest civilian honor — earlier this month. During a ceremony

A carefully monitored, multidisciplinary watch-and-wait strategy can result in excellent rectal preservation and pelvic tumor control for a large majority of select patients with rectal cancer who show a clinical complete response after neoadjuvant therapy.

… Friday, March 1, 2019 A carefully monitored, multidisciplinary watch-and-wait strategy can result in excellent rectal preservation and pelvic tumor control for a large majority of select patients with rectal cancer who show a clinical complete response after neoadjuvant therapy, according to our recent

Learn more about how MSK is developing new treatments for osteosarcoma and other bone cancers.

… Wednesday, September 14, 2016 Summary MSK is leading the way in osteosarcoma treatment, developing new surgical methods that enable many people to be cured and to live full, active lives. Highlights Osteosarcomas are rare tumors; two-thirds of them occur in children and young adults. They most frequently

Researchers from Memorial Sloan Kettering Cancer Center (MSK), in collaboration with an international research team, have discovered that DNA circles can contribute to the development of childhood cancers. The team, led by MSK computational biologist Richard Koche and Anton Henssen of Charité University Hospital Berlin, made this discovery by studying extrachromosomal DNA in neuroblastoma cells. Neuroblastoma develops in immature nerve cells and is the most common form of cancer in infants.

… Monday, December 16, 2019 Researchers from Memorial Sloan Kettering Cancer Center (MSK), in collaboration with an international research team, have discovered that DNA circles can contribute to the development of childhood cancers. The team, led by MSK computational biologist Richard Koche and Anton

An antibody test developed at MSK could shed light on the immune response to the COVID-19 virus.

… Tuesday, September 22, 2020 Summary A test developed by MSK researchers can detect three different antibodies to the COVID-19 virus. The test could help researchers clarify how someone fights off the virus, as well as who might be best protected if they are exposed a second time. Testing for antibodies

Blood pressure should be monitored closely and on an ongoing basis for several months after initiating ibrutinib treatment in patients with chronic lymphocytic leukemia (CLL), according to our retrospective study.

… Wednesday, January 8, 2020 Blood pressure should be monitored closely and on an ongoing basis for several months after initiating ibrutinib treatment in patients with chronic lymphocytic leukemia (CLL), according to our retrospective study published this month in JAMA Network Open . Hypertension is a

根据我们的回顾性研究，在慢性淋巴细胞白血病 (CLL) 患者开始接受伊鲁替尼治疗后，应密切监测其血压，并持续数月。

… Wednesday, January 8, 2020 根据我们本月发表在《美国医学会杂志网络公开》 (JAMA Network Open) 上的回顾性研究，在慢性淋巴细胞白血病 (CLL) 患者开始接受伊鲁替尼治疗后，应密切监测其血压，持续数月。 高血压是临床试验中接受伊鲁替尼治疗的 CLL 患者发生的常见不良事件。我们在非临床试验环境中研究了 CLL 患者中与伊鲁替尼相关的高血压的发展模式、管理策略和长期血管影响。  (1) 我们的结果显示，在接受伊鲁替尼治疗的 247 例 CLL 患者的整个队列中，包括存在和不存在高血压病史的患者，患者的血压均发生显著升高。 我们的结果显示，在接受伊鲁替尼治疗的

… Monday, March 24, 2025 Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and progress.  (1) Metastatic disease develops in about 50% of patients with surgically